Healthcare Commerce as a User-Friendly Experience

| July 7, 2018

article image
Technological advancements occur with such frequency that it’s challenging to stay on top — or ahead — of the Next Big Thing, but successful businesses need to focus attention on advancements that make internal processes easier and more efficient. Highly successful businesses take it one step further and implement solutions that also make their customers’ lives easier. Some technologies address both solutions simultaneously, resulting in a win-win for everyone.

Spotlight

Lusochimica S.p.A.

Lusochimica S.p.A. is an Italian manufacturer of bulk active ingredients for pharmaceuticals (API), having sales offices in Milan and two production plants in Lomagna and Pisa, whose production processes strictly comply with international cGMP standards. Founded in 1964 and belonging to Menarini Group since 1984, Lusochimica S.p.A. incorporated former Laboratori Guidotti Fine Chemicals division starting January 2009, as a result of restructuring of Fine Chemicals operations within Menarini Group.

OTHER ARTICLES

What are the advantages of PCD Pharma Company?

Article | February 17, 2020

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 10, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Spotlight

Lusochimica S.p.A.

Lusochimica S.p.A. is an Italian manufacturer of bulk active ingredients for pharmaceuticals (API), having sales offices in Milan and two production plants in Lomagna and Pisa, whose production processes strictly comply with international cGMP standards. Founded in 1964 and belonging to Menarini Group since 1984, Lusochimica S.p.A. incorporated former Laboratori Guidotti Fine Chemicals division starting January 2009, as a result of restructuring of Fine Chemicals operations within Menarini Group.

Events